This segment focuses on the research, development, and clinical trials of novel medicines for neurological disorders. Longboard Pharmaceuticals is actively involved in preclinical studies, Phase 1, Phase 2, and Phase 3 clinical trials to evaluate the safety and efficacy of its drug candidates. The company utilizes advanced methodologies in drug discovery, including the identification of novel drug targets and the development of innovative therapeutic approaches. The primary therapeutic areas of focus include developmental and epileptic encephalopathies (DEEs), amyotrophic lateral sclerosis (ALS), and other neuroinflammatory disorders. The goal is to improve patient outcomes by providing effective treatments for these debilitating conditions. Longboard's market positioning is strengthened by its focus on unmet medical needs and its strategic partnerships. Future opportunities include expanding the pipeline and securing regulatory approvals. The company is subject to rigorous regulatory oversight and clinical validation processes, including FDA approval. Partnerships with organizations like Beacon Biosignals are key to advancing research and development.